81 FR 37499 - Medical Devices; Ophthalmic Devices; Classification of Nasolacrimal Compression Device

DEPARTMENT OF HEALTH AND HUMAN SERVICES
Food and Drug Administration

Federal Register Volume 81, Issue 112 (June 10, 2016)

Page Range		37499-37500
FR Document		2016-13788

The Food and Drug Administration (FDA) is classifying the nasolacrimal compression device into class I (general controls). The Agency is classifying the device into class I (general controls) in order to provide a reasonable assurance of safety and effectiveness of the device.

Federal Register, Volume 81 Issue 112 (Friday, June 10, 2016)

[Federal Register Volume 81, Number 112 (Friday, June 10, 2016)]
[Rules and Regulations]
[Pages 37499-37500]
From the Federal Register Online  [www.thefederalregister.org]
[FR Doc No: 2016-13788]


=======================================================================
-----------------------------------------------------------------------

DEPARTMENT OF HEALTH AND HUMAN SERVICES

Food and Drug Administration

21 CFR Part 886

[Docket No. FDA-2016-N-1308]


Medical Devices; Ophthalmic Devices; Classification of 
Nasolacrimal Compression Device

AGENCY: Food and Drug Administration, HHS.

ACTION: Final order.

-----------------------------------------------------------------------

SUMMARY: The Food and Drug Administration (FDA) is classifying the 
nasolacrimal compression device into class I (general controls). The 
Agency is classifying the device into class I (general controls) in 
order to provide a reasonable assurance of safety and effectiveness of 
the device.

DATES: This order is effective June 10, 2016. The classification was 
applicable on April 20, 2016.

FOR FURTHER INFORMATION CONTACT: Daniel Fedorko, Center for Devices and 
Radiological Health, Food and Drug Administration, 10903 New Hampshire 
Ave., Bldg. 66, Rm. 2414, Silver Spring, MD 20993-0002, 301-796-6620.

SUPPLEMENTARY INFORMATION:

I. Background

    In accordance with section 513(f)(1) of the Federal Food, Drug, and 
Cosmetic Act (the FD&C Act) (21 U.S.C. 360c(f)(1)), devices that were 
not in commercial distribution before May 28, 1976 (the date of 
enactment of the Medical Device Amendments of 1976), generally referred 
to as postamendments devices, are classified automatically by statute 
into class III without any FDA rulemaking process. These devices remain 
in class III and require premarket approval, unless and until the 
device is classified or reclassified into class I or II, or FDA issues 
an order finding the device to be substantially equivalent, in 
accordance with section 513(i) of the FD&C Act, to a predicate device 
that does not require premarket approval. The Agency determines whether 
new devices are substantially equivalent to predicate devices by means 
of premarket notification procedures in section 510(k) of the FD&C Act 
(21 U.S.C. 360(k)) and part 807 (21 CFR part 807) of the regulations.
    Section 513(f)(2) of the FD&C Act, as amended by section 607 of the 
Food and Drug Administration Safety and Innovation Act (Pub. L. 112-
144), provides two procedures by which a person may request FDA to 
classify a device under the criteria set forth in section 513(a)(1) of 
the FD&C Act. Under the first procedure, the person submits a premarket 
notification under section 510(k) of the FD&C Act for a device that has 
not previously been classified and, within 30 days of receiving an 
order classifying the device into class III under section 513(f)(1) of 
the FD&C Act, the person requests a classification under section 
513(f)(2). Under the second procedure, rather than first submitting a 
premarket notification under section 510(k) of the FD&C Act and then a 
request for classification under the first procedure, the person 
determines that there is no legally marketed device upon which to base 
a determination of substantial equivalence and requests a 
classification under section 513(f)(2) of the FD&C Act. If the person 
submits a request to classify the device under this second procedure, 
FDA may decline to undertake the classification request if FDA 
identifies a legally marketed device that could provide a reasonable 
basis for review of substantial equivalence with the device or if FDA 
determines that the device submitted is not of ``low-moderate risk'' or 
that general controls would be inadequate to control the risks and 
special controls to mitigate the risks cannot be developed.
    In response to a request to classify a device under either 
procedure provided by section 513(f)(2) of the FD&C Act, FDA will 
classify the device by written order within 120 days. This 
classification will be the initial classification of the device.
    On June 27, 2014, Innovatex, Inc., submitted a request for 
classification of the Tear Duct Occluder (originally referred to as the 
Glaucoma Companion Nasolacrimal Compression Device) under section 
513(f)(2) of the FD&C Act. The manufacturer recommended that the device 
be classified into class I (Ref. 1).
    In accordance with section 513(f)(2) of the FD&C Act, FDA reviewed 
the request in order to classify the device under the criteria for 
classification set forth in section 513(a)(1) of the FD&C Act. FDA 
classifies devices into class I if general controls by themselves are 
sufficient to provide reasonable assurance of safety and effectiveness 
of the device for its intended use. After review of the information 
submitted in the de novo request, FDA determined that the device can be 
classified into class I. FDA believes general controls will provide 
reasonable assurance of the safety and effectiveness of the device.
    Therefore, on April 20, 2016, FDA issued an order to the requestor 
classifying the device into class I. FDA

[[Page 37500]]

is codifying the classification of the device by adding 21 CFR 
886.5838.
    The device is assigned the generic name nasolacrimal compression 
device, and it is identified as a prescription device that is fitted to 
apply mechanical pressure to the nasal aspect of the orbital rim to 
reduce outflow through the nasolacrimal ducts.
    The risks to health that may be associated with use of the 
nasolacrimal compression device are improper fit of the device 
(extended or aggressive use of this device may cause sequelae such as 
bruising and/or soreness) and improper use of the device (for the 
uncoordinated, a corneal abrasion may occur inadvertently). General 
controls of the FD&C Act, including compliance with the labeling 
requirements in 21 CFR part 801 and the Quality System Regulation (21 
CFR part 820), are sufficient to mitigate these risks and reasonably 
assure safety and effectiveness. FDA believes that the general controls 
provide reasonable assurance of safety and effectiveness.
    The nasolacrimal compression device is not safe for use except 
under the supervision of a practitioner licensed by law to direct the 
use of the device. As such, the device is a prescription device and 
must satisfy prescription labeling requirements (see 21 CFR 801.109, 
Prescription devices).
    Section 510(l) of the FD&C Act provides that a class I device is 
not subject to the premarket notification requirements under section 
510(k) of the FD&C Act, unless the device is of substantial importance 
in preventing impairment of human health or presents a potential 
unreasonable risk of illness or injury. FDA has determined that the 
device does meet these criteria and, therefore, premarket notification 
is not required for the device. Thus, persons who intend to market this 
device need not submit a premarket notification containing information 
on the nasolacrimal compression device they intend to market prior to 
marketing the device, subject to the limitations on exemptions in 21 
CFR 886.9.

II. Analysis of Environmental Impact

    The Agency has determined under 21 CFR 25.34(b) that this action is 
of a type that does not individually or cumulatively have a significant 
effect on the human environment. Therefore, neither an environmental 
assessment nor an environmental impact statement is required.

III. Paperwork Reduction Act of 1995

    This final order refers to previously approved collections of 
information found in other FDA regulations. These collections of 
information are subject to review by the Office of Management and 
Budget (OMB) under the Paperwork Reduction Act of 1995 (44 U.S.C. 3501-
3520). The collections of information in part 807, subpart E, regarding 
premarket notification submissions, have been approved under OMB 
control number 0910-0120; the collections of information in 21 CFR part 
820, regarding the quality system regulation, have been approved under 
OMB control number 0910-0073; and the collections of information in 21 
CFR part 801, regarding labeling, have been approved under OMB control 
number 0910-0485.

IV. Reference

    The following reference is on display in the Division of Dockets 
Management (HFA-305), Food and Drug Administration, 5630 Fishers Lane, 
Rm. 1061, Rockville, MD 20852, and is available for viewing by 
interested persons between 9 a.m. and 4 p.m., Monday through Friday; it 
is also available electronically at http://www.regulations.gov.

    1. DEN140022: De novo request from Innovatex, Inc., dated June 
27, 2014.

List of Subjects in 21 CFR Part 886

    Medical devices, Ophthalmic goods and services.

    Therefore, under the Federal Food, Drug, and Cosmetic Act and under 
authority delegated to the Commissioner of Food and Drugs, 21 CFR part 
886 is amended as follows:

PART 886--OPHTHALMIC DEVICES

0
1. The authority citation for 21 CFR part 886 continues to read as 
follows:

    Authority: 21 U.S.C. 351, 360, 360c, 360e, 360j, 371.


0
2. Add Sec.  886.5838 to subpart F to read as follows:


Sec.  886.5838  Nasolacrimal compression device.

    (a) Identification. A nasolacrimal compression device is a 
prescription device that is fitted to apply mechanical pressure to the 
nasal aspect of the orbital rim to reduce outflow through the 
nasolacrimal ducts.
    (b) Classification. Class I (general controls). The device is 
exempt from the premarket notification procedures in subpart E of part 
807 of this chapter, subject to the limitations in Sec.  886.9.

    Dated: June 6, 2016.
Leslie Kux,
Associate Commissioner for Policy.
[FR Doc. 2016-13788 Filed 6-9-16; 8:45 am]
 BILLING CODE 4164-01-P

Federal Register / Vol. 81, No. 112 / Friday, June 10, 2016 / Rules and Regulations 37499

(h) Related Information DEPARTMENT OF HEALTH AND device under the criteria set forth in
Refer to MCAI European Aviation Safety HUMAN SERVICES section 513(a)(1) of the FD&C Act.
Agency (EASA) AD No.: 2015–0240, dated Under the first procedure, the person
December 18, 2015; Rotax Aircraft Engines Food and Drug Administration submits a premarket notification under
BRP Service Bulletin SB–912–066 R1/SB– section 510(k) of the FD&C Act for a
914–047 R1 (published as one document), 21 CFR Part 886 device that has not previously been
Revision 1, dated April 23, 2015; Diamond classified and, within 30 days of
Aircraft Industries GmbH Optional Service [Docket No. FDA–2016–N–1308]
receiving an order classifying the device
Bulletin OSB 36–111, dated September 17,
Medical Devices; Ophthalmic Devices; into class III under section 513(f)(1) of
2015; Diamond Aircraft Industries GmbH
Work Instruction WI–OSB 36–111, dated Classification of Nasolacrimal the FD&C Act, the person requests a
September 17, 2015; Diamond Aircraft Compression Device classification under section 513(f)(2).
Service Bulletin No.: DA20–72–04, dated Under the second procedure, rather than
January 22, 2015; Diamond Aircraft AGENCY: Food and Drug Administration, first submitting a premarket notification
Industries GmbH Optional Service Bulletin HHS. under section 510(k) of the FD&C Act
OSB 20–066, dated September 17, 2015; ACTION: Final order. and then a request for classification
Diamond Aircraft Industries GmbH Work under the first procedure, the person
Instruction WI–OSB 20–066, dated SUMMARY: The Food and Drug determines that there is no legally
September 17, 2015; and Scheibe Aircraft Administration (FDA) is classifying the marketed device upon which to base a
GmbH Service Information 02/14–1, dated nasolacrimal compression device into determination of substantial
December 15, 2014, for related information. class I (general controls). The Agency is equivalence and requests a classification
You may examine the MCAI on the Internet classifying the device into class I
at https://www.regulations.gov/
under section 513(f)(2) of the FD&C Act.
#!documentDetail;D=FAA-2016-4878-0002.
(general controls) in order to provide a If the person submits a request to
For information on the availability of the reasonable assurance of safety and classify the device under this second
service documents above, contact the FAA, effectiveness of the device. procedure, FDA may decline to
Small Airplane Directorate, at 816–329–4148. DATES: This order is effective June 10, undertake the classification request if
2016. The classification was applicable FDA identifies a legally marketed device
(i) Material Incorporated by Reference
on April 20, 2016. that could provide a reasonable basis for
(1) The Director of the Federal Register review of substantial equivalence with
approved the incorporation by reference FOR FURTHER INFORMATION CONTACT:
Daniel Fedorko, Center for Devices and the device or if FDA determines that the
(IBR) of the service information listed in this
Radiological Health, Food and Drug device submitted is not of ‘‘low-
paragraph under 5 U.S.C. 552(a) and 1 CFR
part 51. Administration, 10903 New Hampshire moderate risk’’ or that general controls
(2) You must use this service information Ave., Bldg. 66, Rm. 2414, Silver Spring, would be inadequate to control the risks
as applicable to do the actions required by MD 20993–0002, 301–796–6620. and special controls to mitigate the risks
this AD, unless the AD specifies otherwise. cannot be developed.
SUPPLEMENTARY INFORMATION: In response to a request to classify a
(i) Rotax Aircraft Engines BRP Service
Bulletin SB–912–068 and SB–914–049 (co- I. Background device under either procedure provided
published as one document), dated April 16, by section 513(f)(2) of the FD&C Act,
2015. In accordance with section 513(f)(1) of FDA will classify the device by written
(ii) Reserved. the Federal Food, Drug, and Cosmetic order within 120 days. This
(3) For BRP-Powertrain GmbH & CO KG Act (the FD&C Act) (21 U.S.C. classification will be the initial
service information identified in this AD, 360c(f)(1)), devices that were not in classification of the device.
contact BRP-Powertrain GmbH & Co. KG, commercial distribution before May 28, On June 27, 2014, Innovatex, Inc.,
Welser Strasse 32, A–4623 Gunskirchen, 1976 (the date of enactment of the submitted a request for classification of
Austria; phone: +43 7246 601 0; fax: +43 Medical Device Amendments of 1976),
7246 601 9130; Internet: www.rotax-aircraft-
the Tear Duct Occluder (originally
generally referred to as postamendments referred to as the Glaucoma Companion
engines.com.
devices, are classified automatically by Nasolacrimal Compression Device)
(4) You may view this service information
at the FAA, Small Airplane Directorate, 901 statute into class III without any FDA under section 513(f)(2) of the FD&C Act.
Locust, Kansas City, Missouri 64106. For rulemaking process. These devices The manufacturer recommended that
information on the availability of this remain in class III and require the device be classified into class I (Ref.
material at the FAA, call (816) 329–4148. In premarket approval, unless and until 1).
addition, you can access this service the device is classified or reclassified In accordance with section 513(f)(2) of
information on the Internet at http:// into class I or II, or FDA issues an order the FD&C Act, FDA reviewed the
www.regulations.gov by searching for and finding the device to be substantially request in order to classify the device
locating Docket No. FAA–2016–4878. equivalent, in accordance with section under the criteria for classification set
(5) You may view this service information 513(i) of the FD&C Act, to a predicate forth in section 513(a)(1) of the FD&C
that is incorporated by reference at the
device that does not require premarket Act. FDA classifies devices into class I
National Archives and Records
Administration (NARA). For information on approval. The Agency determines if general controls by themselves are
the availability of this material at NARA, call whether new devices are substantially sufficient to provide reasonable
202–741–6030, or go to: http:// equivalent to predicate devices by assurance of safety and effectiveness of
www.archives.gov/federal-register/cfr/ibr- means of premarket notification the device for its intended use. After
locations.html. procedures in section 510(k) of the review of the information submitted in
asabaliauskas on DSK3SPTVN1PROD with RULES

FD&C Act (21 U.S.C. 360(k)) and part the de novo request, FDA determined
Issued in Kansas City, Missouri, on June 1, 807 (21 CFR part 807) of the regulations. that the device can be classified into
2016. Section 513(f)(2) of the FD&C Act, as class I. FDA believes general controls
Pat Mullen, amended by section 607 of the Food and will provide reasonable assurance of the
Acting Manager, Small Airplane Directorate, Drug Administration Safety and safety and effectiveness of the device.
Aircraft Certification Service. Innovation Act (Pub. L. 112–144), Therefore, on April 20, 2016, FDA
[FR Doc. 2016–13542 Filed 6–9–16; 8:45 am] provides two procedures by which a issued an order to the requestor
BILLING CODE 4910–13–P person may request FDA to classify a classifying the device into class I. FDA

VerDate Sep<11>2014 16:32 Jun 09, 2016 Jkt 238001 PO 00000 Frm 00015 Fmt 4700 Sfmt 4700 E:\FR\FM\10JNR1.SGM 10JNR1

Document Created: 2018-02-08 07:36:01
Document Modified: 2018-02-08 07:36:01

Category		Regulatory Information
Collection		Federal Register
sudoc Class		AE 2.7: GS 4.107: AE 2.106:
Publisher		Office of the Federal Register, National Archives and Records Administration
Section		Rules and Regulations
Action		Final order.
Dates		This order is effective June 10, 2016. The classification was applicable on April 20, 2016.
Contact		Daniel Fedorko, Center for Devices and Radiological Health, Food and Drug Administration, 10903 New Hampshire Ave., Bldg. 66, Rm. 2414, Silver Spring, MD 20993-0002, 301-796-6620.
FR Citation		81 FR 37499
CFR Associated		Medical Devices and Ophthalmic Goods and Services

81 FR 37499 - Medical Devices; Ophthalmic Devices; Classification of Nasolacrimal Compression Device

DEPARTMENT OF HEALTH AND HUMAN SERVICESFood and Drug Administration

Federal Register Volume 81, Issue 112 (June 10, 2016)

DEPARTMENT OF HEALTH AND HUMAN SERVICES
Food and Drug Administration